|
1
|
Ferlay J, Ervik M, Lam F, Laversanne M,
Colombet M, Mery L, et al: Global Cancer Observatory: Cancer Today.
International Agency for Research on Cancer (IARC), Lyon, France.
Accessed on October 28, 2024. https://gco.iarc.who.int/today.
|
|
2
|
Alghamdi IG: Epidemiology of gastric
cancer in Saudi Arabia from 2004 to 2017. Mol Clin Oncol.
19(93)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kang YK, Yoon DH, Ryoo BY and Ryu MH:
Recent advances in chemotherapy for advanced gastric cancer. Asia
Pac J Oncol Hematol. 2:67–74. 2010.
|
|
4
|
Baccili Cury Megid T, Farooq AR, Wang X
and Elimova E: Gastric cancer: Molecular mechanisms, novel targets,
and immunotherapies: From bench to clinical therapeutics. Cancers
(Basel). 15(5075)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Guan WL, He Y and Xu RH: Gastric cancer
treatment: Recent progress and future perspectives. J Hematol
Oncol. 16(57)2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Li W, Wei J, Cheng M and Liu M: Unveiling
promising targets in gastric cancer therapy: A comprehensive
review. Mol Ther Oncolytics. 32(200857)2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Arnold M, Ferlay J, van Berge Henegouwen
MI and Soerjomataram I: Global burden of oesophageal and gastric
cancer by histology and subsite in 2018. Gut. 69:1564–1571.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Menard S, Pupa SM, Campiglio M and
Tagliabue E: Biologic and therapeutic role of HER2 in cancer.
Oncogene. 22:6570–6578. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Liu L, Wu N and Li J: Novel targeted
agents for gastric cancer. J Hematol Oncol. 5(31)2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ajani JA, D'Amico TA, Bentrem DJ, Chao J,
Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al:
Gastric cancer, version 2.2022, NCCN clinical practice guidelines
in oncology. J Natl Compr Canc Netw. 20:167–192. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bartley AN, Washington MK, Colasacco C,
Ventura CB, Ismaila N, Benson AB III, Carrato A, Gulley ML, Jain D,
Kakar S, et al: HER2 testing and clinical decision making in
gastroesophageal adenocarcinoma: Guideline from the College of
American pathologists, American society for clinical pathology, and
the American society of clinical oncology. J Clin Oncol.
35:446–464. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ceylan C, Angin YS, Baran NT, Kocaaslan H,
Cengiz E, Guzel M, Saglam K and Aydin C: Relationship between HER2
and clinicopathological data in gastric adenocarcinomas. J Surg
Med. 8:7–11. 2024.
|
|
14
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697.
2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy
versus chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40.
2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lee J, Kim J, Bang YJ, Shitara K,
Tabernero J, van Cutsem E, Enzinger P, Moehler M, Yanez P and
Janjigian YY: Novel HER2-targeting agents in gastric cancer: A
review of recent clinical trials. Cancer Treat Rev.
102(102319)2022.
|
|
17
|
Li W, Zhang X, Du Y, Zhang Y, Lu J, Hu W
and Zhao J: HER2-targeted advanced metastatic
gastric/gastroesophageal junction adenocarcinoma: Treatment
landscape and future perspectives. Biomark Res.
10(71)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Boku N: HER2 positive gastric cancer.
Gastric Cancer. 17:1–12. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hofmann M, Stoss O, Shi D, Buttner R, van
de Vijver M, Kim W, Ochiai A, Ruschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: Results from a
validation study. Histopathology. 52:797–805. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA:
WHO classification of tumours editorial board. The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lin JL, Lin JX, Lin GT, Huang CM, Zheng
CH, Xie JW, Wang JB, Lu J, Chen QY and Li P: Global incidence and
mortality trends of gastric cancer and predicted mortality of
gastric cancer by 2035. BMC Public Health. 24(1763)2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Anderson WF, Camargo MC, Fraumeni JF Jr,
Correa P, Rosenberg PS and Rabkin CS: Age-specific trends in
incidence of noncardia gastric cancer in US adults. JAMA.
303:1723–1728. 2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamangar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 23:700–713. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Abdel-Salam RA, El-Hawary A, Mohamed MA
and Gamil T: Immunohistochemical expression of Her2/neu in gastric
carcinomas in Egyptian patients. J Clin Pathol Diagn. 1:1–6.
2018.
|
|
25
|
Abdi-Rad A, Ghaderi-Sohi S,
Nadimi-Barfroosh H and Emami S: Trend in incidence of gastric
adenocarcinoma by tumor location from 1969-2004: A study in one
referral center in Iran. Diagn Pathol. 1(5)2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cherian JV, Sivaraman R, Muthusamy AK and
Venkataraman J: Stomach carcinoma in the Indian subcontinent: A
16-year trend. Saudi J Gastroenterol. 13:114–117. 2007.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM,
Wang ZN, Li HQ, Zhang SB and Sun Z: The clinicopathological
parameters and prognostic significance of HER2 expression in
gastric cancer patients: A meta-analysis of literature. World J
Surg Oncol. 15(68)2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shan L, Ying J and Lu N: HER2 expression
and relevant clinicopathological features in gastric and
gastroesophageal junction adenocarcinoma in a Chinese population.
Diagn Pathol. 8(76)2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang S, Zheng R, Arnold M, Abnet C, Zeng
H, Zhang S, Chen R, Sun K, Li L, An L, et al: Global and national
trends in the age-specific sex ratio of esophageal cancer and
gastric cancer by subtype. Int J Cancer. 151:1447–1461.
2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Van Cutsem E, Bang YJ, Feng-Yi R, Xu JM,
Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, et
al: HER2 screening data from ToGA: Targeting HER2 in gastric and
gastroesophageal junction cancer. Gastric Cancer. 18:476–484.
2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Azarhoosh R, Ebneghasem R and Besharat S:
HER-2/neu gene amplification in gastric adenocarcinoma and its
relationship with clinical and pathological findings. J
Gastrointest Oncol. 8:1046–1050. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yoshida H, Yamamoto N, Taniguchi H, Oda I,
Katai H, Kushima R and Tsuda H: Comparison of HER2 status between
surgically resected specimens and matched biopsy specimens of
gastric intestinal-type adenocarcinoma. Virchows Arch. 465:145–154.
2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Watson S, Validire P, Cervera P, Zorkani
N, Scriva A, Lemay F, Tournigand C, Perniceni T, Garcia ML,
Bennamoun M, et al: Combined HER2 analysis of biopsies and surgical
specimens to optimize detection of trastuzumab-eligible patients in
eso-gastric adenocarcinoma: A GERCOR study. Ann Oncol.
24:3035–3039. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Liu Z, Xu H, You W, Pan K and Li W:
Helicobacter pylori eradication for primary prevention of gastric
cancer: Progresses and challenges. J Natl Cancer Cent. 4:299–310.
2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen YC, Malfertheiner P, Yu HT, Kuo CL,
Chang YY, Meng FT, Wu YX, Hsiao JL, Chen MJ, Lin KP, et al: Global
prevalence of Helicobacter pylori infection and incidence of
gastric cancer between 1980 and 2022. Gastroenterology.
166:605–619. 2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Roy PS, Nyodu T, Hazarika M, Saikia BJ,
Bhuyan C, Inamdar A, Nyuthe CW, Borthakur B and Sharma JD:
Prevalence of HER2 expression and its correlation with
clinicopathological parameters in gastric or gastroesophageal
junction adenocarcinoma in North-East Indian population. Asian Pac
J Cancer Prev. 20:1139–1145. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Cheng X: A comprehensive review of HER2 in
cancer biology and therapeutics. Genes (Basel).
15(903)2024.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zheng HC, Li XH, Hara T, Masuda S, Yang
XH, Guan YF and Takano Y: Mixed-type gastric carcinomas exhibit
more aggressive features and indicate the histogenesis of
carcinomas. Virchows Arch. 452:525–534. 2008.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Matsuoka T and Yashiro M: Molecular
mechanism for malignant progression of gastric cancer within the
tumor microenvironment. Int J Mol Sci. 25(11735)2024.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Canale M, Casadei-Gardini A, Ulivi P,
Arechederra M, Berasain C, Lollini PL, Fernandez-Barrena MG and
Avila MA: Epigenetic mechanisms in gastric cancer: Potential new
therapeutic opportunities. Int J Mol Sci. 21(5500)2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ma C, Wang X, Guo J, Yang B and Li Y:
Challenges and future of HER2-positive gastric cancer therapy.
Front Oncol. 13(1080990)2023.PubMed/NCBI View Article : Google Scholar
|
